{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:18:51Z","timestamp":1791256731973,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/cad.0b013e3283584f75","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T03:35:26Z","timestamp":1345779326000},"page":"66-72","source":"Crossref","is-referenced-by-count":20,"title":["Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro"],"prefix":"10.1097","volume":"24","author":[{"given":"Yash","family":"Somnay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April D.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvi","family":"Kunnimalaiyaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthusamy","family":"Kunnimalaiyaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210227","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1634\/theoncologist.2008-0207","article-title":"Carcinoid tumors.","volume":"15","author":"Pinchot","year":"2008","journal-title":"Oncologist"},{"key":"R2-7-20210227","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.soc.2006.05.002","article-title":"Carcinoid tumors.","volume":"15","author":"Sippel","year":"2006","journal-title":"Surg Oncol Clin N Am"},{"key":"R4-7-20210227","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.cco.0000198018.53606.62","article-title":"Treatment of advanced carcinoid tumors.","volume":"15","author":"Lal","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"R5-7-20210227","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1517\/14656566.9.15.2617","article-title":"Pharmacotherapy of neuroendocrine cancers.","volume":"15","author":"Modlin","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R6-7-20210227","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5694\/j.1326-5377.2010.tb03742.x","article-title":"Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management.","volume":"15","author":"Modlin","year":"2010","journal-title":"Med J Aust"},{"key":"R7-7-20210227","first-page":"291","article-title":"AKT and PTEN expression in human gastrointestinal carcinoid tumors.","volume":"15","author":"Pitt","year":"2009","journal-title":"Am J Transl Res"},{"key":"R8-7-20210227","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jamcollsurg.2009.03.006","article-title":"Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.","volume":"15","author":"Pitt","year":"2009","journal-title":"J Am Coll Surg"},{"key":"R9-7-20210227","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1245\/s10434-009-0591-5","article-title":"Inhibition of phosphatidylinositol 3-kinaseAkt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.","volume":"15","author":"Pitt","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R10-7-20210227","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.","volume":"15","author":"Yap","year":"2011","journal-title":"J Clin Oncol"},{"key":"R11-7-20210227","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.bmcl.2008.04.074","article-title":"Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.","volume":"15","author":"Bilodeau","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"R12-7-20210227","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.","volume":"15","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R13-7-20210227","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-11-0606","article-title":"MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.","volume":"15","author":"Cheng","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R14-7-20210227","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.","volume":"15","author":"Hirai","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"R15-7-20210227","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1210\/jc.2011-1054","article-title":"The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK12 inhibitor AZD6244 in the inhibition of thyroid cancer cells.","volume":"15","author":"Liu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-7-20210227","doi-asserted-by":"crossref","first-page":"G245","DOI":"10.1152\/ajpgi.00420.2002","article-title":"Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells.","volume":"15","author":"Sippel","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R19-7-20210227","first-page":"576","article-title":"Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors.","volume":"15","author":"Pinchot","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"R20-7-20210227","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000329386","article-title":"From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.","volume":"15","author":"Wiedenmann","year":"2011","journal-title":"Neuroendocrinology"},{"key":"R21-7-20210227","first-page":"3","article-title":"The phosphatidylinositol 3-kinaseAkt signaling pathway in neuroendocrine tumors.","volume":"15","author":"Somnay","year":"2012","journal-title":"Global J Biochem"},{"key":"R22-7-20210227","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise.","volume":"15","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"key":"R23-7-20210227","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer.","volume":"15","author":"Wong","year":"2010","journal-title":"Curr Opin Genet Dev"},{"key":"R24-7-20210227","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1615\/CritRevOncog.v17.i1.60","article-title":"Targeting PI3 kinaseAKTmTOR signaling in cancer.","volume":"15","author":"Sheppard","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"R26-7-20210227","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A - biological function and clinical utility in neuroendocrine tumor disease.","volume":"15","author":"Modlin","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R27-7-20210227","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/sj.cdd.4400691","article-title":"Novel survivin-related members of the inhibitor of apoptosis (IAP) family.","volume":"15","author":"Wenzel","year":"2000","journal-title":"Cell Death Differ"},{"key":"R28-7-20210227","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/cncr.24180","article-title":"Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning.","volume":"15","author":"Drozdov","year":"2009","journal-title":"Cancer"},{"key":"R29-7-20210227","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2010.08426.x","article-title":"Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis.","volume":"15","author":"Frenzel","year":"2011","journal-title":"Br J Haematol"},{"key":"R30-7-20210227","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1158\/1078-0432.CCR-10-1664","article-title":"X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise.","volume":"15","author":"Kashkar","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R31-7-20210227","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605704","article-title":"Elevated XIAP expression alone does not confer chemoresistance.","volume":"15","author":"Seeger","year":"2010","journal-title":"Br J Cancer"},{"key":"R32-7-20210227","doi-asserted-by":"crossref","first-page":"G798","DOI":"10.1152\/ajpgi.00015.2008","article-title":"Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor.","volume":"15","author":"Pritchard","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e3283584f75","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:17:41Z","timestamp":1620933461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201301000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283584f75","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}